Patents by Inventor Guoliang Xu

Guoliang Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11999998
    Abstract: The present invention relates to a novel modification of a 5-methylcytosine nucleic acid catalyzed by a Cmd1 enzyme and an application thereof. The present inventors have for the first time discovered Cmd1, a 5mC-modifying enzyme, which can link a glyceryl group to a 5mC methyl carbon of a methylated nucleic acid through a carbon-carbon single bond, and this is a new epigenetic modification.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: June 4, 2024
    Assignee: Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences
    Inventor: Guoliang Xu
  • Patent number: 11862830
    Abstract: The present disclosure provides a membrane electrode assembly (MEA) with high-efficiency water and heat management for a direct ethanol fuel cell (DEFC), and a fabrication method therefor, and belongs to the technical field of fuel cells. In the MEA for a DEFC in the present disclosure, a cathode catalyst layer is designed to be convex and ordered and an anode catalyst layer is designed to be concave and ordered, which is conducive to the timely discharge of the generated heat. The MEA for a DEFC can be fabricated by gradually fabricating each layer of the MEA on an inner surface and an outer surface of a proton-exchange membrane (PEM) or by step-by-step dip coating on an anode support tube. The present disclosure can effectively improve the working capacity of the cell.
    Type: Grant
    Filed: August 25, 2021
    Date of Patent: January 2, 2024
    Assignee: Jiangsu University
    Inventors: Dong Tang, Guoliang Xu, Yubin Han, Shengyao Shi, Yang Xiao
  • Publication number: 20230213343
    Abstract: The present disclosure provides a method for obtaining confidence of a measurement value based on multi-sensor fusion and an autonomous vehicle, which includes that: a first measurement value position of a positioning component on a target vehicle is determined at a first moment, and a second measurement value position of the positioning component is determined at a second moment, where the first moment is earlier than the second moment; first distance information is acquired according to the first measurement value position and the second measurement value position; inertial measurement information and wheel speedometer information of the target vehicle from the first moment to the second moment are determined; second distance information is acquired based on the inertial measurement information and the wheel speedometer information; and confidence of a target measurement value corresponding to the second moment is acquired according to the first distance information and the second distance information.
    Type: Application
    Filed: December 7, 2022
    Publication date: July 6, 2023
    Inventors: Feng CHENG, Wenjie LIU, Xiaochen QIU, Guoliang XU, Renlan CAI
  • Publication number: 20230197992
    Abstract: The present disclosure provides a membrane electrode assembly (MEA) with high-efficiency water and heat management for a direct ethanol fuel cell (DEFC), and a fabrication method therefor, and belongs to the technical field of fuel cells. In the MEA for a DEFC in the present disclosure, a cathode catalyst layer is designed to be convex and ordered and an anode catalyst layer is designed to be concave and ordered, which is conducive to the timely discharge of the generated heat. The MEA for a DEFC can be fabricated by gradually fabricating each layer of the MEA on an inner surface and an outer surface of a proton-exchange membrane (PEM) or by step-by-step dip coating on an anode support tube. The present disclosure can effectively improve the working capacity of the cell.
    Type: Application
    Filed: August 25, 2021
    Publication date: June 22, 2023
    Applicant: Jiangsu University
    Inventors: Dong TANG, Guoliang XU, Yubin HAN, Shengyao SHI, Yang XIAO
  • Publication number: 20230183795
    Abstract: The present invention relates to a novel modification of a 5-methylcytosine nucleic acid catalyzed by a Cmd1 enzyme and an application thereof. The present inventors have for the first time discovered Cmd1, a 5mC-modifying enzyme, which can link a glyceryl group to a 5mC methyl carbon of a methylated nucleic acid through a carbon-carbon single bond, and this is a new epigenetic modification.
    Type: Application
    Filed: August 24, 2017
    Publication date: June 15, 2023
    Inventor: Guoliang Xu
  • Publication number: 20220213070
    Abstract: The present invention provides a class of compounds inhibiting TDG activity. Specifically, the present invention provides a compound having a novel structure as shown in formula I. The small molecule inhibitor of the present invention has an excellent inhibitory effect on TDG.
    Type: Application
    Filed: April 14, 2020
    Publication date: July 7, 2022
    Applicant: EPITAS BIOSCIENCES (SHANGHAI) CO., LTD.
    Inventors: Weixing ZHU, Shenglian YANG, Guoliang XU
  • Patent number: 9534259
    Abstract: The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: January 3, 2017
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Yi Zhang, Qin Feng, Yuki Okada, Guoliang Xu
  • Publication number: 20150147758
    Abstract: The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject.
    Type: Application
    Filed: October 28, 2014
    Publication date: May 28, 2015
    Inventors: Yi ZHANG, Qin FENG, Yuki OKADA, Guoliang XU
  • Publication number: 20130065814
    Abstract: The present invention relates to use of synthetic factors in reprogramming somatic cells to become induced pluripotent stem cells and other cell lineages. Specifically, the present application relates to fusion proteins containing proteins encoded by cell totipotency-related genes and transcription regulatory domains, their coding sequences, expression vectors, and compositions. The present application also relates to methods for reprogramming somatic cells to become induced pluripotent stem cells and other cell lineages, and cells containing the fusion proteins or the coding sequences.
    Type: Application
    Filed: March 7, 2011
    Publication date: March 14, 2013
    Applicant: SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CAS
    Inventors: Guoliang Xu, Yang Wang
  • Publication number: 20100151453
    Abstract: The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject.
    Type: Application
    Filed: October 14, 2008
    Publication date: June 17, 2010
    Inventors: YI ZHANG, QIN FENG, YUKI OKADA, GUOLIANG XU
  • Publication number: 20090269751
    Abstract: The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject.
    Type: Application
    Filed: October 14, 2008
    Publication date: October 29, 2009
    Inventors: YI ZHANG, QIN FENG, YUKI OKADA, GUOLIANG XU
  • Patent number: 7442685
    Abstract: The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject.
    Type: Grant
    Filed: June 14, 2004
    Date of Patent: October 28, 2008
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Yi Zhang, Qin Feng, Yuki Okada, Guoliang Xu
  • Publication number: 20050048634
    Abstract: The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject.
    Type: Application
    Filed: June 14, 2004
    Publication date: March 3, 2005
    Inventors: Yi Zhang, Qin Feng, Yuki Okada, Guoliang Xu